Eyal Talor - CEL SCI Chief Scientific Officer
| CVM Stock | USD 0.60 0.10 14.29% |
Executive
Dr. Eyal Talor, Ph.D., is Chief Scientific Officer of CELSCI Corporation since 2009.
| Age | 68 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Address | 8229 Boone Boulevard, Vienna, VA, United States, 22182 |
| Phone | 703 506 9460 |
| Web | https://cel-sci.com |
Eyal Talor Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eyal Talor against CEL SCI stock is an integral part of due diligence when investing in CEL SCI. Eyal Talor insider activity provides valuable insight into whether CEL SCI is net buyers or sellers over its current business cycle. Note, CEL SCI insiders must abide by specific rules, including filing SEC forms every time they buy or sell CEL SCI'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eyal Talor over a week ago Acquisition by Eyal Talor of 1256 shares of CEL SCI at 1.91 subject to Rule 16b-3 | ||
Eyal Talor over three months ago Acquisition by Eyal Talor of 182000 shares of CEL SCI at 1.36 subject to Rule 16b-3 | ||
Eyal Talor over six months ago Acquisition by Eyal Talor of 1256 shares of CEL SCI at 1.91 subject to Rule 16b-3 |
CEL SCI Management Efficiency
The company has Return on Asset of (0.6141) % which means that on every $100 spent on assets, it lost $0.6141. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.502) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of December 2024, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Total Assets are very stable compared to the past year. As of the 29th of December 2024, Non Current Assets Total is likely to grow to about 28.5 M, while Return On Tangible Assets are likely to drop (1.01).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark MD | Cyclacel Pharmaceuticals | 63 | |
| Alfred Dadson | Agenus Inc | N/A | |
| Michael Jones | BioCryst Pharmaceuticals | 54 | |
| Stephanie Fagan | Agenus Inc | N/A | |
| Jinky Rosselli | BioCryst Pharmaceuticals | N/A | |
| Dhan Chand | Agenus Inc | N/A | |
| Philip George | BioCryst Pharmaceuticals | N/A | |
| Charles Gayer | BioCryst Pharmaceuticals | 53 | |
| Jennifer Buell | Agenus Inc | 49 | |
| Nils MD | Agenus Inc | N/A | |
| John Bluth | BioCryst Pharmaceuticals | 51 | |
| Salisa Hauptmann | BioCryst Pharmaceuticals | N/A | |
| Clayton Fletcher | BioCryst Pharmaceuticals | N/A | |
| Eric Humes | Agenus Inc | N/A | |
| Todd MD | Agenus Inc | N/A | |
| Dr MBA | Agenus Inc | N/A | |
| Zack Armen | Agenus Inc | N/A | |
| Grace Kim | Cyclacel Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 |
CEL SCI Corp Leadership Team
Elected by the shareholders, the CEL SCI's board of directors comprises two types of representatives: CEL SCI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CEL. The board's role is to monitor CEL SCI's management team and ensure that shareholders' interests are well served. CEL SCI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CEL SCI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Young, Independent Director | ||
| Giovanni MD, Acting Officer | ||
| Geert Kersten, Chief Executive Officer, Treasurer, Director | ||
| Robert Watson, Independent Director | ||
| John Cipriano, Senior Vice President - Regulatory Affairs | ||
| Patricia Prichep, Senior Vice President - Operations, Corporate Secretary | ||
| Bruno Baillavoine, Independent Director | ||
| Geert Esq, Treasurer Officer | ||
| Eyal Talor, Chief Scientific Officer | ||
| Daniel Zimmerman, Senior Vice President - Research, Cellular Immunology |
CEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CEL SCI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 50.04 M | ||||
| Shares Outstanding | 63.81 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 10.46 % | ||||
| Number Of Shares Shorted | 4.43 M | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 4.52 X | ||||
| Price To Sales | 11,797 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.